tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients
Article Quality & Performance Metrics
Readership in this journal
SteadyRanked #6 of 24 articles by views in basic and clinical neuroscience
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.
| Reference Key |
shuvaev2014onkogematologityrosine
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;V. A. Shuvaev;M. S. Fominykh;I. S. Martynkevich;V. Y. Udaleva;N. A. Potikhonova;M. N. Zenina;K. M. Abdulkadyrov |
| Journal | basic and clinical neuroscience |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.